Company intelligence / Profile preview
Daye
London, England, United Kingdomyourdaye.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Daye launched a CBD-infused tampon product commercially since around late 2019 with a subscriber base (~60k users). It has developed a novel at-home vaginal microbiome screening kit that uses tampons to collect samples more comfortably than traditional swabs. This test helps assess risk factors like STIs and recurrent infections. The company also operates a telemedical platform connecting users with gynecological specialists who provide personalized treatment recommendations delivered directly to customers. Future plans include expanding into contraception support as well as PCOS/endometriosis diagnostics.
- Therapeutic areas
- Women's Health
- Modalities
- Small moleculeIn-vitro diagnostic testing technologyTelemedical platform services for gynecological health treatments
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Daye.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daye.